Skip to main content
La Tunisie Médicale logoLink to La Tunisie Médicale
. 2022 Apr 1;100(4):285–294.

Update meta-analysis from biomedical literature about MTHFR’polymorphisms and the CML’ risk

Associations: polymorphismes du MTHFR et leucémie myéloïde chronique. Méta analyse de la littérature biomédicale

Fatma Turki 1,4, Nour Louati 2, Hassen Kamoun 4, Leila Keskes 3, Tarek Rebaii 4, Rim Frikha 1,4
PMCID: PMC9476263  PMID: 36155899

Abstract

Background: The MTHFR gene polymorphisms are closely related to the chronic myeloid leukemia (CML). Case-control studies have associated the MTHFR polymorphisms and susceptibility to CML but the results were not conclusive.

The aim of this study was to assess this association through an update meta-analysis.

Methods: Electronic searches were conducted to select published studies prior to juin 2018.

Pooled odds ratios (OR) with corresponding 95% confidence interval (95% CI) and stratification analysis were performed under different genetic comparison models and ethnicity.

Results: Totally, 17 and 12 case-control studies including CML cases and controls were enrolled in the meta-analysis respectively for C677T and A1298C polymorphism and CML risk. A poor association between the C677T (T vs C ; OR= 1,28; IC95%= [1,01;1,63]; p=0,04) and the one not significant between the A1298C (C vs A ; OR= 1,52; IC95%= [0,92; 2,51]; p= 0,1)polymorphisms and the CML risk for overall population were found.

Conclusions: the results of this meta-analysis suggested no significant association between C677T and A1298C polymorphisms and CML risk leading to consider other factors such us folic acid intake, gene-gene and gene- environment interactions.

Keywords: Methylene tetrahydrofolatereductase, myeloid chronic leukemia, polymorphism, Risk.

INTRODUCTION:

The cause of human cancer is a consequence of complex interplay between genetic predisposition and environmental factors. Susceptibility to different types of leukemia seems to be related to polymorphisms in multiple genes and various genetic events during blood cell development(1 ). Chronic myelogenous leukemia (CML), an example treated in this meta-analysis, is a myeloproliferative disease characterized by the reciprocal translocation t (9; 22) (q34; q11) and bcr-abl fusion transcript(2 ). It’s a common malignancy of hematopoietic stem cells distinguished by an abnormal accumulation of white blood cells in the bone marrow that interferes with the normal production of blood cells. Since the introduction of Imatinib in 2000, the annual mortality in CML has decreased from 10%-20% down to 1%-2% (3, 4 ). Clinical and biological aspects of CML are well investigated, but the factors that cause individuals ’ susceptibilities to CML are still not fully understood(3 ). Assessment of causes of CML may be beneficial for clinical management and prevention.

CML are likely to be affected by the metabolic fate of folic acid(5 ). Folate methylation plays an essential role in DNA synthesis and methylation processes(6 ). Folate deficiency have been associated with hypomethylation and uracil mis-incorporation into DNA during replication, increasing the risk of chromosomal aberrations and facilitating the onset of oncogenic processes(7 ). Folate metabolism requires the optimal activity of various enzymes(8 ).

5, 10 methylene tetrahydrofolate reductase (MTHFR) is one of the important enzymes of the folate cycles(9 ). It irreversibly reduces 5, 10 methylene tetrahydrofolate to 5 methyl tetrahydrofolate, the primary form of serum folate and carbon donor for the remethylation of homocysteine to methionine(10 ).

The MTHFR gene is located on the short arm of chromosome 1(1p36.3).

There are two commonly occurring polymorphisms in the MTHR gene: C677T and A1298C. C677T occurs in exon 4 and results in alanine to valine substitution at codon 222, while a second common polymorphism, A1298C in exon 7, results in a glutamate to alanine substitution at codon 429(11 ).

To date, several studies performed in different countries have assessed the association between MTHFR’ polymorphisms and susceptibility to malignant hemopathies like acute lymphoblastic leukemia (12 ) and CML. But, the results were inconclusive and conflicting (13, 14 ). Moreover, the previous meta-analyses had limited sample sizes and so the statistical study still not powerful to demonstrate a significant association (15, 16, 17 ). Therefore, we carried out our meta-analysis which will be the most exhaustive in order to determine the relationship between the MTHFR polymorphisms and the risk of development of CML according to the models and the ethnicity.

METHODES :

Search strategy:

A comprehensive search that investigated the association between the MTHFR C677T or A1298C genetic variants and the risk of adult CML published before June 2018 was conducted in PubMed electronic databases. The following combined descriptor terms were used:

(« Methylenetetrahydrofolate reductase » OR « MTHFR ») AND (« Chronic myeloid leukemia »). The search included only journal articles. All references cited in the studies were extensively reviewed to identify additional published articles.

Studies selection :

Published studies before June 2018; were selected in the analysis according to these following inclusion criteria: (1 ) case-control study; (2 ) study evaluating the association between C677T and A1298C polymorphisms and susceptibility to CML; and (3 ) study presenting available data on the distribution of MTHFR gene polymorphisms in cases and in control groups which are sufficient for calculating odds ratio. For multiple studies using the same groups of patients or controls, the study with the largest sample size was included in the meta-analysis. We excluded articles which are reviews and not publications. Data of Meta-analyses which are also excluded will be used for comparison and discussion later.

As a whole, this meta-analysis was carried out according to the preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA).

Data extraction :

Two independent investigators checked each report and extracted and tabulated the following data from eligible studies: name of the first author, year of publication, country of origin, ethnicity of the study population, numbers and genotype distributions of cases and controls.

Statistical analysis :

The meta-analysis, using the software http://bioinfo.genyo.es/metagenyo/ (18 ), examined different genetic comparison models namely allele contrast model (« T vs. C » or  « C vs. A »), recessive model (« CC+CT vs. TT » or « AA+AC vs. CC »), dominant model (« TT+TC vs. CC » or « CC+AC vs. AA »), homozygote model (« TT vs. CC » or « CC vs. AA ») and heterozygote model (« CT vs. CC » or « AC vs. AA ») for estimation of the association between MTHFR C677T and/or A1298C polymorphisms and CML risk, respectively.

The genotype distribution was assessed for Hardy-Weinberg Equilibrium (HWE) to check study quality, P(HWE)< 0,05 showed statistical significance and so control genotype might not be in HWE and should be excluded from the meta-analysis (18 ).

The odds ratio (OR) and 95% confidence interval (CI) were calculated using data for genotype distribution. These association tests results evaluated the association’ strength between MTHFR polymorphisms and CML risks. If the value 1 was not in the range of CI, it was considered that there is an increased relative risk in one group compared with the other (18 ).

The heterogeneity was determined by calculating I² metric statistic. I²<25%, 25%<I²<50% and I²>50% were interpreted as low, moderate, and high degrees of heterogeneity, respectively (19 ). When no heterogeneity was found with p >0, 05 or I² < 50%, a fixed effect model was chosen to estimate the pooled ORs with their corresponding 95%CIs. Otherwise, a random-effects model was used (20 ).

Forest plots were provided by the meta-analysis to estimate the global result of all studies.

Funnel plot, a graphical test, was used to check if publication bias exists or not. So asymmetry of the funnel plot suggested a possible publication bias. The Egger’s test could be used ; p<0,05 was considered as a potential statistical publication bias(21 ).

Subgroup analysis also was performed according to the ethnicities.

Sensitivity analyses were conducted to examine whether the individual study influenced the pooled results.

RESULTS :

Search of published reports :

A flow chart depicting the study selection process is shown in Figure 1.

Figure. 1. Flow diagram for study inclusion in the meta-analysis and reasons for study exclusion.

Figure. 1. Flow diagram for study inclusion in the meta-analysis and reasons for study exclusion

.26 articles were identified based on various combinations of the keywords listed in the Methods and focused on the relationship between MTHFR gene SNPs and the risk of CML. On these articles, 9 were reviews and 3 were meta-analyses. Therefore, only 17 studies qualified for inclusion in this meta-analysis.

Study characteristics:

Characteristics of the 17 articles included in the meta-analysis were shown in Table 1, Table 2 . The studies were conducted in various populations of different ethnicities, as Asian (6 studies), Caucasian (5 studies), Mixed (5 studies) and one on African population for MTHFR C677T polymorphism. However, the A1298C polymorphism was distributed in 4, 2, 1 and 5 studies for Asian, Caucasian, African and Mixed population respectively.

Table 1. Study characteriscs : Publication year ; ethnicity ; polymorphisms studied; number and mean age of both cases and controls.

First author

Publication year

Ethnicity (country)

Polymorphisms studied

Cases

Controles

Number

Mean Age (years)

Number

Mean Age (years)

Deligezer 2003(25 )

2003

Caucasian (Turkey)

C677T

131 (F/M= 70/61)

45,9

161 (F/M= 112/48)

39

Hur 2006(22 )

2006

Asian (Korea)

C677T, A1298C

40 (F/M= 13/27)

50

200 (F/M= 72/128

34

Chen 2006(6)

2006

Asian (China)

C677T

7 (NA)

NA

157 (NA)

NA

Moon 2007(26 )

2007

Asian (Korea)

C677T, A1298C

115 (F/M= 40/75)

43,8

434 (F/M=238/19)

41,4

Barbosa(7)

2008

Mixed (Brasil)

C677T, A1298C

67 (F/M= 30/36)

44

100 (F/M=47/53)

29

Kim 2009(27 )

2009

Asian (Korea)

C677T, A1298C

149 (F/M= 55/94)

50,4

1700 (F/M= 879/821)

52,2

Ismail 2008(28 )

2009

Mixed (Jordan)

C677T, A1298C

149 (NA)

NA

170 (NA)

NA

Vahid 2010(23 )

2010

Mixed (Iran)

C677T, A1298C

38 (F/M= 19/19)

45

97(F/M= 50/47)

44,8

Jankovic 2011(29 )

2011

Caucasian (Serbia)

C677T

43 (NA)

NA

26 (NA)

NA

Lordelo 2012(24 )

2012

Caucasian

C677T, A1298C

41 (NA)

NA

155 (NA)

NA

Lordelo 2012(24 )

2012

Mixed (Brasil)

C677T, A1298C

64 (NA)

NA

118 (NA)

NA

Hussein 2012(30 )

2012

Asian (India)

C677T

43 (NA)

39,5

251 (NA)

41,5

Jakoljevic 2013(31 )

2012

Caucasian (Serbia)

C677T

52 (F/M= 24/28)

NA

53 (F/M= 24/30)

NA

Dorgham 2014(32 )

2014

African (Algeria)

C677T, A1298C

90 (NA)

45,9

100 (NA)

47,3

Banescu 2014(33 )

2014

Caucasian (Romania)

C677T, A1298C

151 (F/M= 65/86)

51

305 (F/M= 179/126)

47

Rabab M Aly 2014(14)

2014

Mixed (Egypt)

C677T, A1298C

85 (F/M= 40/45)

46,7

100 (F/M= 49/51)

48,2

Korshied 2014(13 )

2014

MIxed (Egypt)

C677T, A1298C

97 (F/M= 51/46)

NA

130 (F/M= 68/62)

NA

F: female; M: male; NA: not available

Table 2. Table 2. Distribution of MTHFR C677T and A1298C genotypes in cases and controls and calculation of P value.

Study

Distribution of C677T MTHFR genotype(n)

HWE P value

Distribution of A1298 MTHFR genotype(n)

HWE P value

Case

Contol

Case

Control

CC

CT

TT

CC

CT

TT

AA

AC

CC

AA

AC

CC

Deligezer 2003 (25 )

72

50

9

74

73

14

0,5006

Hur 2006(22 )

13

17

10

80

80

40

0,0184

31

7

2

116

78

6

0,0944

Chen 2006(6 )

2

2

3

72

66

19

0,522

Moon 2007(26 )

43

45

27

144

196

94

0,0779

74

33

8

307

120

7

0,2189

Barbosa 2008(7 )

46

19

2

65

29

6

0,2701

41

23

3

63

32

5

0,7221

Kim 2009(27 )

54

72

26

540

863

297

0,1326

97

49

5

1147

500

53

0,8678

Ismail 2008(28 )

63

67

19

94

66

10

0,722

59

68

22

76

81

13

0,1724

Vahid 2010(23 )

24

11

3

56

37

4

0,4872

12

19

7

39

36

22

0,0211

Jankovic 2011(29 )

17

21

5

6

16

4

0,2247

Lordelo 2012(24 )

15

21

5

74

66

15

0,9594

26

15

0

68

79

8

0,0132

Lordelo 2012(24 )

31

26

7

66

48

4

0,1787

35

28

1

51

64

3

0,0844

Hussein 2012(30 )

28

8

7

180

61

10

0,106

Jakoljevic 2013(31 )

8

29

5

13

33

7

0,057

Dorgham 2014(32 )

8

35

40

48

38

3

0,1649

27

31

26

50

42

5

0,3082

Banescu 2014(33 )

58

68

25

154

116

35

0,0727

67

68

16

149

119

37

0,0868

Rabab M Aly 2014(14 )

30

44

11

45

49

6

0,1192

32

38

15

40

51

9

0 ,199

Korshied 2014(13 )

41

45

11

65

52

13

0,5872

54

37

6

55

65

10

0,1206

P HWE: P value for Hardy-weinberg equilibrium

Only one study (Hur s’ study (22 )) was removed, since the distributions were not in accordance with the HWE, for the C677T polymorphism. Likewise, the distribution of the A1298C genotypes in controls were not in accordance with the WHE in two studies: Vahid(23 ) and Lordelo (24 ) reports.

1362 cases and 4357 controls were found in these studies for MTHFR C677T polymorphism. The allele and variants genotype frequency of each study were listed in Table 2 . In the case group, the range of T allele frequencies was from 16 to 45%. It changed from 17 to 36% for Asian population, from 23 to 33% for Caucasian population and from 16 to 29% for mixed population. The T allele frequency was 45% for African population. In the control group of C677T polymorphism, the allele T frequencies varied from 14 to 38%.

In the same way, a total of 1086 cases and 3609 controls were enrolled in these studies for MTHFR A1298C polymorphism. For the case group, the C allele frequencies varied from 11 to 34%. For African population, the C allele frequency was 34%. It changed from 11 to 34%for Asian population, from 18 to 28% for Caucasian population and from 19 to 31% for mixed population. While in the control group the rate of C allele frequency varied from 15 to 30%.

Meta- analysis results :

The meta-analysis of association studies were summarized in Table 3 .

Table 3. Table 3 a. Odds ratio (OR), heterogeneity results and publication bias for the genetic contrasts of MTHFR gene C677T polymorphisms for CML risks.

Model C677T

Ethnicity

Number

Heterogeneity ‘s tests

Association ‘s tests

Publication bias

P-value

OR

CI

P-value

P-value Egger’s test)

Allele contrast (Tvs C)

Overall

17

80,82%

0,0001

1,28

[1.01; 1.63]

0,039721

0,4453

African

1

NA

NA

6,87

[4.27; 11.03]

0

NA

Asian

6

44,68%

0,1076

1,04

[0.89; 1.22]

0,58702

0,0513

Caucasian

5

66,6%

0,0175

0,98

[0.69; 1.39]

0,935452

0,3034

Mixed

5

13,94%

0,3254

1,35

[1.12; 1.63]

0,001918

0,1257

Recessive model (TT vs TC+CC)

Overall

17

63,8%

0,0002

1,67

[1.16; 2.41]

0,005973

0,1311

African

1

NA

NA

26,66

[7.8; 91.14]

1,64E-07

NA

Asian

6

56,57%

0,0421

1,60

[0.97; 2.63]

0,063045

0,0364

Caucasian

5

0%

0,5732

1,14

[0.77; 1.68]

0,508805

0,1149

Mixed

5

24,07%

0,2609

1,78

[1.13; 2.8]

0,012638

0,6376

Dominant model (CC vs TT+TC)

Overall

17

69,79%

0,0001

1,23

[0.94; 1.6]

0,127175

0,4733

African

1

NA

NA

10,97

[4.74; 25.42]

2,25E-08

NA

Asian

6

0

0,5513

0,94

[0.75; 1.18]

0,586297

0,0904

Caucasian

5

68,69%

0,0124

0,95

[0.57; 1.58]

0,842135

0,3761

Mixed

5

0%

0,5631

1,38

[1.08; 1.77]

0,009783

0,105

Homozygote (TT vs CC)

Overall

17

73,57%

0,0001

1,79

[1.13; 2.83]

0,01326

0,1821

African

1

NA

NA

80

[19.89; 321.7]

7E-10

NA

Asian

6

56,79%

0,0411

1,53

[0.89; 2.65]

0,126373

0,0403

Caucasian

5

44,69%

0,1242

1,19

[0.78; 1.8]

0,419753

0,1361

Mixed

5

28,73%

0,23

2,05

[1.28; 3.28]

0,002904

0,5168

Heterozygote (TT vs CC)

Overall

17

51,02%

0,0082

1,10

[0.88; 1.38]

0,397935

0,8322

African

1

NA

NA

5,53

[2.29; 13.29]

0,000136

NA

Asian

6

0%

0,8978

0,84

[0.66; 1.08]

0,171749

0,5167

Caucasian

5

61,23%

0,0354

0,95

[0.59; 1.53]

0,845969

0,4038

Mixed

5

0%

0,8226

1,29

[1.001; 1.68]

0,048527

0,0384

I2 : degree of heterogenity ; OR : Odds Ratio ; IC: confidence interval

By examining the heterogeneity tests ‘results, we took into consideration the random effect model since the p value<0,05 and I²>50% for the C677T and A1298C polymorphisms, except one heterozygous model of the A1298C polymorphism.

Overall, we have found a poor association between CML risk and the C677T polymorphism under the allele contrast model (Figure 2 ); recessive model (TT vs. TC+CC) and homozygous model (TT vs. CC). For the dominant model (CC vs. TT+TC) and the heterozygous model (TC vs. CC), the association is not significant.

Figure 2 A. Forest plot of C677T polymorphisms and CML under the allele contrast model.

Figure 2 A. Forest plot of C677T polymorphisms and CML under the allele contrast model

According to the ethnicity, a significant association between CML risk and C677T variant in African population was described under all models (Table 3a ).

Moreover, in the overall population, we have found no significant association between the A1298C polymorphism and the CML risk, respectively for the allele contrast, the recessive and the homozygous model (Figure 3 ).

Figure 2 B. Forest plot of C677T and A1298C polymorphisms under different models.

Figure 2 B. Forest plot of C677T and A1298C polymorphisms under different models

Subgroup analysis by ethnicity showed a magnitude effect in African population under all models except those heterozygote model (CA vs. AA) whose association was not significant (OR= 1, 37, 95%CI=0, 7071-2,6423, p=0,3527)(Table 3b ).

Table 4.  Table 3 b. Odds ratio (OR), heterogeneity results and publication bias for the genetic contrasts of MTHFR gene A1298C polymorphisms for CML risks.

Model A1298C

Ethnicity

Number

Heterogeneity ‘s tests

Association ‘s tests

Publication bias

P-value

OR

CI

P-value

P-value Egger’s test)

Allele contrast (C vs A)

Overall

12

70,61%

0,0001

1,06

[0.85; 1.33]

0,610745

0,2087

African

1

NA

NA

2,66

[1.72; 4.13]

1,17E-05

NA

Asian

4

53,73%

0,0903

1,08

[0.79; 1.49]

0,616595

0,3436

Caucasian

2

78,63%

0,0305

0,77

[0.37; 1.59]

0,488287

NA

Mixed

5

52,04%

0,0799

0,99

[0.75; 1.31]

0,951556

0,3622

Recessive model (CC vs AC+AA)

Overall

12

58,74%

0,0052

1,51

[0.93; 2.45]

0,097038

0,744

African

1

NA

NA

8,25

[2.99; 22.69]

4,38E-05

NA

Asian

4

56,31%

0,0763

1,54

[0.67; 3.52]

0,305413

0,7443

Caucasian

2

0%

0,3463

0,80

[0.44; 1.48]

0,486417

NA

Mixed

5

0%

0,4084

1,53

[0.97; 2.43]

0,067319

0,1337

Dominant model (AA vs CC+AC)

Overall

12

60,14%

0,0037

0,99

[0.78; 1.27]

0,971503

0,1982

African

1

NA

NA

2,24

[1.22; 4.12]

0,008968

NA

Asian

4

60,22%

0,0565

1,04

[0.68; 1.61]

0,846408

0,5194

Caucasian

2

82,04%

0,0183

0,77

[0.29; 1.99]

0,590829

NA

Mixed

5

38,73%

0,163

0,91

[0.71; 1.16]

0,435625

0,5895

Homozygote (CC vs AA)

Overall

12

58,86%

0,005

1,52

[0.92; 2.51]

0,106747

0,5131

African

1

NA

NA

9,63

[3.32; 27.95]

3,09E-05

NA

Asian

4

44,7%

0,1432

1,65

[0.95; 2.87]

0,073228

0,944

Caucasian

2

32,95%

0,222

0,88

[0.46; 1.66]

0,691687

NA

Mixed

5

25%

0,2548

1,43

[0.88; 2.32]

0,143511

0,1763

Heterozygote (CA vs AA)

Overall

12

46,02%

0,0404

0,94

[0.75; 1.17]

0,585394

0,133

African

1

NA

NA

1,37

[0.71; 2.64]

0,352779

NA

Asian

4

63,73%

0,0407

0,99

[0.61; 1.61]

0,980956

0,5831

Caucasian

2

79,93%

0,0256

0,83

[0.33; 2.08]

0,694699

NA

Mixed

5

8,51%

0,358

0,84

[0.65; 1.09]

0,197205

0,7727

Publication’s bias:

Egger’s test was applied to assess possible publication bias of the included studies. For C677T polymorphism, Table 3a showed publication bias for Asian population under recessive model and homozygote model (TT vs. CC) and for mixed population under heterozygote model (TC vs. CC). The A1298C polymorphism didn’t show any publication bias according to Egger’s test represented on Table 3b .

Begg’s Funnel plots was used showing a symmetrical shape for the two polymorphisms (Figure 4 ).

Figure 3. Funnel plot analysis of potential publication biais. A: Funnel plots analysis for publication biais between MTHFR C677Tpolymorphism and CML ; B : Funnel plots analysis for publication biais between MTHFR A1298C polymorphism and CML.

Figure 3. Funnel plot analysis of potential publication biais. A: Funnel plots analysis for publication biais between MTHFR C677Tpolymorphism and CML ; B : Funnel plots analysis for publication biais between MTHFR A1298C polymorphism and CML.

Sensitivity analysis

Sensitivity analyses of both MTHFR C677T and A1298C indicated that no study has significantly influenced the pooled ORs.

DISCUSSION:

In the current meta-analysis, the relationship was explored between the polymorphisms of MTHFR and CML involving 1362 cases and 4357 controls for the C677T and 1086 cases and 3609 controls for the A1298C variant.

In the overall population, the prevalence of T allele (for the C677T) and the C allele (for the A1298C) ranged from 16 to 45% and from 11 to 34%, respectively. These frequencies were largely presented in the African population. This finding could explain the significant association that we have found, among other reasons, between the two polymorphisms and the CML risk in the African population.

In fact, a poor association was described between the C677T MTHFR polymorphism and CML risk, with the allele contrast model, the recessive and the homozygous model. These results were not consistent with a previous published meta-analysis by Li et al (17 ).

The stratification analysis by ethnicities showed a significant association for African population, suggesting a possible role of ethnic differences in the genetic background and environmental factors regarding the C677T polymorphisms and the risk of CML, especially since the T allele frequency varied by ethnicities.

Concerning the A1298C polymorphism, no association between for the allele contrast, the recessive and the homozygous models in the overall population was described. Subgroup analysis by ethnicity showed a magnitude effect in African population under all models except that heterozygote model (CA vs. AA) whose association was not significant. These results were not consistent with the last meta-analysis (17 ).

Previously, many studies indicated the association between the polymorphisms of the MTHFR gene and CML with inconclusive results. The inconsistent conclusions are due to many reasons leading to the low statistical power. They may be also the result of fundamental differences and heterogeneity between studies like the selection of controls, age distribution and life style factors.

Heterogeneity between studies is a critical problem which must be conducted. To avoid the potential heterogeneity, carefully publication search, strict studies inclusion criteria, precise data extraction, and strict statistical analysis were performed in this meta-analysis. First of all, the distributions of the C677T genotypes in controls were not in accordance with the HWE in one study(22 ). In the same way, the distribution of the A1298C genotypes in controls were not in accordance with the WHE in two studies (23, 24 ). So these reports whose P (HWE) < 0, 05 might not be in HWE should be excluded from the meta-analysis. Moreover, high heterogeneities emerged in comparisons between MTHFR C677T and A1298C polymorphisms in overall, Asian and Caucasian populations under different genetic models.

Heterogeneities cannot be avoided and may result from selection of the control groups, study design, ethnicity differences and lifestyle factors.

Substantial publication bias was found for the C677T polymorphism in Asian population under recessive model, homozygote model (TT vs. CC), and in Mixed population under heterozygote model (TC vs. CC). The A1298C polymorphism didn’t show any publication bias according to Egger’s test. So there is always a certain degree of publication bias, since only published studies were included in this meta-analysis. Non-significant or negative results may be unpublished.

Likewise, the results of sensitivity analysis showed that no individual study influenced the pooled ORs, indicating the results of this meta-analysis are stable.

It should be noted that the use of only “Pubmed” database may skew our results. So, adding indexed publications in other biomedical databases such as Scopus or Web of Science may prevent publications bias and improve our study’conclusion.

Considering the limitations of this meta-analysis, the results should be interpreted with caution.

CONCLUSION:

In conclusion, this meta-analysis suggested poor and no association between C677Tand A1298C polymorphisms respectively, and CML risk. However, due to the limitations of this study, these results should be interpreted with caution and still require future large-scale studies to confirm their accuracy. Moreover, considering that CML is a complex disease with a multifactorial etiology, the development of adult CML might be associated with other factors such us folic acid intake, gene-gene and gene-environment interactions in order to provide more conclusive evidence regarding the genetic susceptibility to adult CML.

References

  1. Schnakenberg Eckart, Mehles Andrea, Cario Gunnar, Rehe Klaus, Seidemann Kathrin, Schlegelberger Brigitte, Elsner Holger A, Welte Karl H, Schrappe Martin, Stanulla Martin. BMC medical genetics. 1. Vol. 6. Springer; 2005. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population; pp. 1–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gabert J, Beillard E, Van der Velden VHJ, Bi W, Grimwade David, Pallisgaard N, Barbany G, Cazzaniga Gianni, Cayuela Jean-Michel, Cave H. Leukemia. 12. Vol. 17. Nature Publishing Group; 2003. Standardization and quality control studies of ‘real-time’quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program; pp. 2318–2357. [DOI] [PubMed] [Google Scholar]
  3. Quintás-Cardama Alfonso, Cortes Jorge E. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clinic Proceedings. 2006;81:973–988. doi: 10.4065/81.7.973. [DOI] [PubMed] [Google Scholar]
  4. Jabbour Elias, Kantarjian Hagop. American journal of hematology. 3. Vol. 93. Wiley Online Library; 2018. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring; pp. 442–459. [DOI] [PubMed] [Google Scholar]
  5. Frazer Rachel, Irvine Alexandra E, McMullin Mary Frances. The Ulster medical journal. 1. Vol. 76. Ulster Medical Society; 2007. Chronic myeloid leukaemia in the 21st century; p. 8. [PMC free article] [PubMed] [Google Scholar]
  6. Chen Bao-An, Jiang Ni, Ji Mei-Ju, Hou Peng, Lu Zu-Hong, Gao Chong, Ding Jia-Hua, Sun Yun-Yu, Wang Jun, Cheng Jian. A new method for 5, 10-methylenetetrahydrofolate reductase single nucleotide polymorphisms genotyping used to study susceptibility of hematological malignancy. Zhongguo shi yan xue ye xue za zhi. 2006;14(6):1069–1073. [PubMed] [Google Scholar]
  7. Barbosa Cynara Gomes, Souza Claudio Lima, Moura Neto José Pereira de, Arruda Maria da Glória Bomfim, Barreto José Henrique, Reis Mitermayer Galvão, Goncalves Marilda Souza. Genetics and molecular biology. Vol. 31. SciELO Brasil; 2008. Methylenetetrahydrofolate reductase polymorphisms in myeloid leukemia patients from Northeastern Brazil; pp. 29–32. [Google Scholar]
  8. Guenther Brian D, Sheppard Christal A, Tran Pamela, Rozen Rima, Matthews Rowena G, Ludwig Martha L. Nature structural biology. 4. Vol. 6. Nature Publishing Group; 1999. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia; pp. 359–365. [DOI] [PubMed] [Google Scholar]
  9. Wiemels Joseph L, Smith Rosalyn N, Taylor G Malcolm, Eden Osborn B, Alexander Freda E, Greaves Mel F, investigators United Kingdom Childhood Cancer Study. Proceedings of the National Academy of Sciences. 7. Vol. 98. National Acad Sciences; 2001. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia; pp. 4004–4009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Miranda-Vilela Ana Luisa, Lordelo Graciana Souza. Role of Methylenetetrahydrofolate reductase (Mthfr), Glutathione S-transferases (Gsts M1 and T1) and haptoglobin (hp) gene polymorphisms in susceptibility to chronic myeloid leukemia (CML) J Hematol Thromb Dis. 2013;1(103):2. [Google Scholar]
  11. van der Put Nathalie MJ, Gabreëls Fons, Stevens Erik MB, Smeitink Jan AM, Trijbels Frans JM, Eskes Tom KAB, van den Heuvel Lambert P, Blom Henk J. The American Journal of Human Genetics. 5. Vol. 62. Elsevier; 1998. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? pp. 1044–1051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Frikha Rim. Assessment of the relationship between methylenetetrahydrofolate reductase polymorphism and acute lymphoblastic leukemia: Evidence from an updated meta-analysis. https://journals.sagepub.com/ doi/abs/10.1177/1078155219900914. J Oncol Pharm Practice. :1–13. doi: 10.1177/1078155219900914. [DOI] [PubMed] [Google Scholar]
  13. Khorshied M, Shaheen I, Khalil R. Methylene tetrahydrofolate reductase (MTHFR) gene polymorphisms in chronic myeloid leukemia: an Egyptian study. Med Oncol. 2013;31 doi: 10.1007/s12032-013-0794-2. [DOI] [PubMed] [Google Scholar]
  14. Aly R M, Taalab M M, Ghazy H F. MTHFR A1298C and C677T gene polymorphisms and susceptibility to chronic myeloid leukemia in Egypt. Int J Clin Exp Pathol. 2014;7(5):2571–2578. [PMC free article] [PubMed] [Google Scholar]
  15. Li B, Zhang J, Wang L, Li Y, Ai Jin J, L. MTHFR genetic polymorphisms may contribute to the risk of chronic myelogenous leukemia in adults: a meta-analysis of 12 genetic association studies. Tumor Biol. 2014;35(5):4233–4245. doi: 10.1007/s13277-013-1554-9. [DOI] [PubMed] [Google Scholar]
  16. He H, He G, Wang T, Cai J, Wang Y. Methylenetetrahydrofolate reductase gene polymorphisms contribute to acute myeloid leukemia and chronic myeloid leukemia susceptibilities: Evidence from meta-analyses - ProQuest. https://www.proquest.com/openview/0d6f2a1d1b5495e2c831349c84cb5e83/1?pqorigsite=gscholar&cbl=1226362. Cancer Epidemiology. 2022;38(5):471–478. doi: 10.1016/j.canep.2014.07.002. [DOI] [PubMed] [Google Scholar]
  17. Li Chen, Yichao Jin, Jiaxin Liu, Yueting Zhang, Qin Lu, Tonghua Yang. Methylenetetrahydrofolate reductase gene polymorphism and risk of chronic myelogenous leukemia: a meta-analysis. J buon. 2015;20:1534–1545. [PubMed] [Google Scholar]
  18. Martorell-Marugan J, Toro-Domínguez D, Alarcón-Riquelme M, Carmona-Saez P, Metagenyo A web tool for meta-analysis of genetic association studies. BMC Bioinformatics. 2017;18:563–563. doi: 10.1186/s12859-017-1990-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Garcia-Orad A. A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2013;13(6):498–506. doi: 10.1038/tpj.2012.44. [DOI] [PubMed] [Google Scholar]
  20. Gurion R, Gafter-Gvili A, Vidal L, Leader A, Ram R, Shacham-Abulafia A. Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica. 2013;98(1):95–102. doi: 10.3324/haematol.2012.063172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Egger Matthias, Smith George Davey, Schneider Martin, Minder Christoph. Bias in meta-analysis detected by a simple, graphical test. https://www.bmj.com/content/315/7109/629. BMJ. 1997;315:629–629. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hur M, Park J Y, Cho H C, Lee K M, Shin H Y, Cho H I. Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population. Clin Lab Haematol. 2006;28(3):154–159. doi: 10.1111/j.1365-2257.2006.00769.x. [DOI] [PubMed] [Google Scholar]
  23. Vahid P, Farnaz R, Zaker F, Farzaneh A, Parisa R. Methylenetetrahydrofolate Reductase Gene Polymorphisms and Risk of Myeloid Leukemia: Table 1. Lab Med. 2010;41(8):490–494. [Google Scholar]
  24. Lordelo G S, Miranda-Vilela A L, Akimoto A K, Alves Pcz, Hiragi C O, Nonino A. Association between methylene tetrahydrofolate reductase and glutathione S-transferase M1 gene polymorphisms and chronic myeloid leukemia in a Brazilian population. Genet Mol Res GMR. 2012;11(2):1013–1026. doi: 10.4238/2012.April.19.6. [DOI] [PubMed] [Google Scholar]
  25. C Banescu,, M Lancu,, A.P Trifa,, I Mascarie, The methylenetetrahydrofolate reductase (MTHFR) 677 C>T polymorphism increases the risk of developing chronic myeloid leukemia-a case-control study. Tumour Biol. 2015;36(4):3101–3107. doi: 10.1007/s13277-014-2946-1. [DOI] [PubMed] [Google Scholar]
  26. Moon Hee Won, Kim Tae Young, Oh Bo Ra, Min Hyun Chung, Cho Han Ik, Bang Soo Mee, Lee Jae Hoon, Yoon Sung Soo, Lee Dong Soon. Leukemia research. 9. Vol. 31. Elsevier; 2007. MTHFR 677CC/1298CC genotypes are highly associated with chronic myelogenous leukemia: a case-control study in Korea; pp. 1213–1217. [DOI] [PubMed] [Google Scholar]
  27. S Hussain,, H Naqvi,, S Raza,, al T. and. Methylenetetrahydrofolate reductase C677T genetic polymorphisms and risk of leukaemia among the North Indian population. Cancer Epidemiol. 2012;36(4):227–231. doi: 10.1016/j.canep.2012.02.008. [DOI] [PubMed] [Google Scholar]
  28. K Jankovic, E Malisic, M Cavic, S Radulovic, A Jankovic. Association between methylenetetrahydrofolate reductase polymorphism C677T and risk of chronic myeloid leukemia in Serbian population. Leuk Lymphoma. 2012;53(7):1327–1330. doi: 10.3109/10428194.2011.645210. [DOI] [PubMed] [Google Scholar]
  29. S Dorgham,, M Aberkane,, W Boughrara, Association between methylene-tetrahydrofolate reductase gene polymorphisms and chronic myeloid leukemia. Bull Cancer. 2014;101(9):803–807. doi: 10.1684/bdc.2014.1953. [DOI] [PubMed] [Google Scholar]
  30. Deligezer Ugur, Akisik Ebru, Dalay Nejat. Molecular Diagnosis. 3. Vol. 7. Springer; 2003. Genotyping of the MTHFR gene polymorphism, C677T in patients with leukemia by melting curve analysis; pp. 181–185. [DOI] [PubMed] [Google Scholar]
  31. Kim Hee Nam, Kim Yeo-Kyeoung, Lee Il-Kwon, Yang Deok-Hwan, Lee Je-Jung, Shin Min-Ho, Park Kyeong-Soo, Choi Jin-Su, Park Moo Rim, Jo Deog Yeon. Leukemia research. 1. Vol. 33. Elsevier; 2009. Association between polymorphisms of folate-metabolizing enzymes and hematological malignancies; pp. 82–87. [DOI] [PubMed] [Google Scholar]
  32. Ismail Said I, Ababneh Nida A, Awidi Abdallah. Methylenetetrahydrofolate reductase (MTHFR) genotype association with the risk of chronic myelogenous leukemia. J Med J. 2009;43(1):8–14. [Google Scholar]
  33. Jankovic RN, Jakovljevic K, Cavic M, Malisic E. Journal of Clinical Oncology. 15_suppl. Vol. 29. American Society of Clinical Oncology; 2011. Relation of methylenetetrahydrofolate reductase C677T polymorphism to chronic myeloid leukemia in Serbia. pp. 6581–6581. [Google Scholar]

Articles from La Tunisie Médicale are provided here courtesy of Tunisian Society of Medical Sciences

RESOURCES